Skip to main content
SpringerLink
Log in

Ferric maltol in iron deficiency anaemia in patients with inflammatory bowel disease: a guide to its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Ferric maltol (Feraccru®) is an option for the oral treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD). In the ferric maltol complex, iron is stabilized in the ferric form (thereby minimizing the potential for mucosal toxicity), while also making the iron highly available for absorption (allowing relatively low dosages of elemental iron to be administered). In patients with IDA associated with IBD who were unable take oral ferrous iron, oral ferric maltol 30 mg twice daily rapidly improved haemoglobin levels and other anaemia-related parameters. It is generally well tolerated, with treatment-related adverse events being mild to moderate in severity and gastrointestinal in nature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211–22.

    Article  PubMed  Google Scholar 

  2. Gomollon F, Gisbert JP. Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. Drugs. 2013;73(16):1761–70.

    Article  CAS  PubMed  Google Scholar 

  3. Stein J, Hartmann F, Dignass A. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599–610.

    Article  CAS  PubMed  Google Scholar 

  4. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–23.

    Article  CAS  PubMed  Google Scholar 

  5. Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis. 2012;6(3):267–75.

    Article  PubMed  Google Scholar 

  6. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis. 2009;15(10):1485–91.

    Article  PubMed  Google Scholar 

  7. de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm Bowel Dis. 2003;9(5):316–20.

    Article  PubMed  Google Scholar 

  8. Goldberg ND. Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2013;6:61–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006;12(12):1101–6.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Feraccru 30 mg hard capsules: summary of product characteristics. London: European Medicines Agency; 2016.

  11. Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther. 1998;12(9):845–8.

    Article  CAS  PubMed  Google Scholar 

  12. Barrand MA, Callingham BA, Dobbin P, et al. Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat. Br J Pharmacol. 1991;102(3):723–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Barrand MA, Callingham BA. Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat. Br J Pharmacol. 1991;102:408–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Singh RK, Barrand MA. Lipid peroxidation effects of a novel iron compound, ferric maltol:a comparison with ferrous sulphate. J Pharm Pharmacol. 1990;42:276–9.

    Article  CAS  PubMed  Google Scholar 

  15. Kelsey SM, Blake DR, Hider RC, et al. Absorption of ferric maltol, a novel ferric iron compound, in iron-deficient subjects. Clin Lab Haematol. 1989;11(3):287–8.

    Article  CAS  PubMed  Google Scholar 

  16. Kelsey SM, Hider RC, Bloor JR, et al. Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test. J Clin Pharm Ther. 1991;16(2):117–22.

    Article  CAS  PubMed  Google Scholar 

  17. Reffitt DM, Burden TJ, Seed PT, et al. Assessment of iron absorption from ferric trimaltol. Ann Clin Biochem. 2000;37(Pt 4):457–66.

    Article  CAS  PubMed  Google Scholar 

  18. Bokemeyer B, Krummenerl A, Maaser C, et al. A pharmacokinetic study of ferric maltol (ST10; Fe-M) at 3 dosages in inflammatory bowel disease (IBD) patients with iron deficiency [abstract no. P581]. J Crohns Colitis. 2015;9(Suppl 1):S370.

  19. Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21(3):579–88.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Schmidt C, Ahmad T, Tulassay Z, et al. Long-term treatment with ferric maltol is effective and well tolerated in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 open-label study [abstract no. P0357]. United European. Gastroenterol J. 2015;3(5 Suppl):A250.

    Google Scholar 

  21. Büning C, Ahmad T, Bokemeyer B, et al. Correcting iron deficiency anaemia in IBD with oral ferric maltol: use of proton pump inhibitors does not affect efficacy [abstract no. P521]. J Crohns Colitis. 2015;9(Suppl 1):S339–S40.

  22. Stallmach A, Buning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16(18):2859–67.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: B. Bokemeyer, Gastroenterology Practice, Minden, Germany; R. Janknegt, Orbis Medical Centre, Sittard-Geleen, The Netherlands.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K.A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest. During the peer review process, the manufacturer of ferric maltol was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific merit.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Ferric maltol in iron deficiency anaemia in patients with inflammatory bowel disease: a guide to its use. Drugs Ther Perspect 32, 226–231 (2016). https://doi.org/10.1007/s40267-016-0310-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0310-9

Keywords

Search

Navigation